$5.85
0.17% today
NYSE, Apr 01, 06:13 pm CET
ISIN
US64157F1030
Symbol
NVRO
Sector

Nevro Stock price

$5.84
+0.12 2.10% 1M
+0.25 4.47% 6M
+2.12 56.99% YTD
-7.48 56.16% 1Y
-66.49 91.93% 3Y
-94.14 94.16% 5Y
-42.09 87.82% 10Y
NYSE, Closing price Mon, Mar 31 2025
+0.00 0.00%
ISIN
US64157F1030
Symbol
NVRO
Sector

Key metrics

Market capitalization $224.09m
Enterprise Value $183.04m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.45
P/S ratio (TTM) P/S ratio 0.55
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth -3.92%
Revenue (TTM) Revenue $408.52m
EBIT (operating result TTM) EBIT $-94.70m
Free Cash Flow (TTM) Free Cash Flow $-29.55m
Cash position $292.53m
EPS (TTM) EPS $-3.05
P/E forward negative
P/S forward 0.55
EV/Sales forward 0.45
Short interest 5.13%
Show more

Is Nevro a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Nevro Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Nevro forecast:

12x Hold
100%

Analyst Opinions

12 Analysts have issued a Nevro forecast:

Hold
100%

Financial data from Nevro

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
409 409
4% 4%
100%
- Direct Costs 153 153
5% 5%
37%
255 255
8% 8%
63%
- Selling and Administrative Expenses 284 284
9% 9%
70%
- Research and Development Expense 52 52
5% 5%
13%
-81 -81
8% 8%
-20%
- Depreciation and Amortization 14 14
25% 25%
3%
EBIT (Operating Income) EBIT -95 -95
5% 5%
-23%
Net Profit -113 -113
23% 23%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Nevro directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nevro Stock News

Neutral
Business Wire
11 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is...
Neutral
PRNewsWire
28 days ago
REDWOOD CITY, Calif. , March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results.
Neutral
PRNewsWire
about one month ago
MILWAUKEE , Feb. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
More Nevro News

Company Profile

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Head office United States
CEO Kevin Thornal
Employees 1,099
Founded 2006
Website www.nevro.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today